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The effect of oral co-administration of nutrients on intestinal drug absorption is a function of 
drug dissolution, gastrointestinal (GI) residence time and intestinal membrane transport. Nu- 
trient effects on GI residence time may influence the availability of the drug for absorption when 
dissolution is rate controlling; alternatively, nutrient effects on membrane transport pathways 
may dictate variability in drug absorption when these pathways are rate limiting. This report 
describes nutrient effects on the absorption variability of the anticonvulsant-antiarrhythmic drug, 
phenytoin (PHT). Numerous reports, detailing clinical failure to maintain drug plasma levels 
within the narrow therapeutic index of PHT, have implicated phenytoin-nutrient interactions 
as (possibly) causative. Absorption variability due to limited time for drug dissolution during GI 
transit was studied by measuring PHTplasma concentrations with time following oral dosage in 
dogs. Variability in intestinal uptake from PHT solutions as a function of nutrient inclusion was 
studied by measuring steady-state membrane permeabilities from intestinal perfusions and ini- 
tial-rate uptakes by intestinal rings in rats. 
INTRODUCTION dissolution or membrane transport. 
Specific drug-nutrient interactions affecting 
intestinal absorption that have been reported 
in the scientific literature include drug-nu- 
trient competition for active transport sites [ 1 ] ; 
nutrient effects on drug stability or metabo- 
lism; and nutrient binding, complexation and 
chelation of drugs [ 21. Case studies in the clin- 
ical literature which involve nutrient effects on 
drug absorption frequently appear for drugs 
possessing a narrow therapeutic index with the 
serious consequences of effective under- or ov- 
erdosage [ 31. It appears that some of these ef- 
fects may be more general when drug absorp- 
tion is critically rate limited by either 
Delay or feedback control of stomach emp- 
tying by nutrient intake results in an increase 
in the GI residence time of the drug, thereby 
permitting greater extent of drug dissolution. 
Phenytoin is a weakly acidic drug (pK, = 8.1) 
possessing poor intrinsic aqueous solubility 
(S, = 100 mA4) and a high membrane-water 
partition coefficient (log PC= 2.4) at 37°C 
[ 4,5]. These physicochemical properties sug- 
gest that PHT intestinal absorption is dissolu- 
tion rate controlled. 
It has recently been suggested that sodium 
co-transport of nutrients in the small intestine 
enhances paracellular uptake of dissolved sol- 
utes [ 61 and that this process operates through 
the generation of local osmotic gradients [7]. 
Since intestinal water absorption follows so- 
dium uptake, this is likely a consequence of both 
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convection-induced reduction of aqueous resis- 
tance to drug transport near the mucosal mem- 
brane and the generation of solvent drag of drug 
through paracellular pathways. Phenytoin’s 
high lipophilicity suggests that transcellular 
membrane transport is not rate limiting for in- 
testinal absorption. However, the drug’s molec- 
ular size (M.W. 252) makes it a candidate for 
variable paracellular uptake as a function of 
nutrient input. 
MATERIALS AND METHODS 
The effect of increasing drug GI residence 
time on drug plasma levels was investigated by 
the oral administration of 12.5 mg/kg body 
weight phenytoin free acid (Sigma Chemical) 
in a gelatin capsule to four beagle dogs. Con- 
trols were compared to drug co-administered 
with an 80 calorie (20 g) oral glucose load (Col- 
Dex, Fernadle Labs) or 80 calories of an enteral 
nutrient solution (Osmolite, Ross Labs). Os- 
molite contains protein and lipid as well as car- 
bohydrate calories. Total administered fluid 
volume in each treatment was 150 ml. Blood 
samples were drawn up to 8 hours post-admin- 
istration and GI pH and time of stomach emp- 
tying were monitored by radiotelemetry (Hei- 
delberg capsule, Electra-Medical Devices) [ 81. 
An additional experiment was performed in 
which the above PHT and nutrient co-admin- 
istration treatments were given to a dog through 
a duodenal fistula. Elimination kinetics were 
determined by intravenous (IV) infusion of so- 
dium phenytoin (Dilantin Injection, Parke 
Davis - Warner Lambert) intravenously at 5 
mg/kg body weight over 10 minutes and 0.5 mg/ 
kg body weight over 1 minute in each of the dogs. 
As a result of the findings in the dog studies, 
attempts to quantify the impact of fed-state bile 
salt output on PHT dissolution were under- 
taken. Rotating disc dissolution experiments 
were carried out at 37’ C with varying concen- 
trations of sodium taurocholate in the same 
baseline solutions that were used for control in 
intestinal perfusions and ring studies. 
The effect of nutrient input on intestinal drug 
uptake from solution was investigated by rat je- 
junal perfusion of 80 ,&f phenytoin solutions at 
300 mOsm/kg and pH 6.5 as controlled by 10 
n-&f Mes buffer (Sigma Chemical). Baseline 
solutions contained 100 m&f sodium chloride 
and 5 mM potassium chloride. Solution osmo- 
lality was adjusted using choline chloride. Con- 
trol solutions were compared with co-perfusion 
of D-ghCOSe (Sigma Chemical) and calcium 
chloride with respect to the jejunal uptake of 
phenytoin. Jejunal lengths of 4-6 cm were per- 
fused at 0.5 ml/min so that aqueous resistance 
to drug transport would not dominate mem- 
brane resistance [ 91 for this high-uptake drug. 
An aqueous diffusion coefficient was required 
to calculate the aqueous resistance. This pa- 
rameter (D,,=8.4~ lop6 cm/s) was obtained 
in rotating disc dissolution experiments by 
measuring dissolution flux versus the square 
root of rotational speed [lo]. Water transport 
was monitored by the inclusion of 0.01% 
poly (ethylene glycol) (PEG ) 4000 traced with 
1,2- [“Cl PEG 4000 (New England Nuclear, 
specific activity 4.4 x lo5 dpm/pmol) as a non- 
absorbable marker. Steady-state drug uptake 
was observed by 30 minutes and phenytoin di- 
mensionless membrane permeabilities, cor- 
rected for water transport, were calculated as 
previously reported [ 111. 
Intestinal ring incubations in drug solutions 
were carried out to obtain initial rate uptake 
data. Segments of rat intestine were everted on 
a glass rod and cut into rings (wet weight lo- 
30 mg). Composition, pH and osmolality of the 
baseline incubation solution were the same as 
those solutions used for rotating disc dissolu- 
tion and intestinal perfusion experiments. Up- 
take of 4- [14C]phenytoin (Amersham, specific. 
activity 2.2 x 10’ dpm/pmol) traced solutions 
was linear up to 5 minutes. Co-incubations of 
PHT with D-glucose and calcium chloride were 
performed for 3 minutes and PHT uptake (nor- 
malized for tissue weight) was determined as 
previously reported [ 12 1. 
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Phenytoin plasma and perfusate concentra- 
tions were measured by an HPLC assay [ 131. 
Radiolabeled [ 14C] PEG 4000 in perfusate and 
[14C]phenytoin taken up by intestinal rings, 
which were later dissolved in Scintigest 
(Fisher), were measured by liquid scintillation 
counting on a Beckman model 9000. Osmolal- 
ity was measured by a Wescor vapor pressure 
osmometer. Plasma and perfusate levels of D- 
glucose were measured by a hexokinase assay 
(Sigma Chemical). Significant treatment dif- 
ferences in the dog pharmacokinetic and rat 
perfusion results were evaluated using a paired 
t-test in which a value of p IO.05 was consid- 
ered statistically significant. 
RESULTS AND DISCUSSION 
The IV clearance of PHT was independent 
of dose (elimination half-life was 3-6 hours in 
all dogs). The radiotelemetry-generated GI pH 
profiles (pH axis labeled 1 to 7) are shown with 
the plasma PHT concentration versus time 
profiles in dogs in Fig. 1. These data were ob- 
tained following oral administration of a Hei- 
delberg capsule and a PHT capsule with 150 ml 
total fluid volume. In particular, dog no. 1 emp- 
tied the Heidelberg capsule immediately after 
drug administration in the fasted state and 
showed the lowest PHT plasma levels. Peak 
PHT plasma levels and area under the drug 
concentration versus time curves were posi- 
tively correlated with time to stomach empty- 
ing in the fasted dog controls (Table 1). Stom- 
ach emptying following 20 gram glucose co- 
administration occurred at 2 hours in 3 of the 4 
dogs and is consistent with a stomach-duo- 
denal feedback loop for glucose which is known 
to operate at 0.7 kcal/min (0.17 g/min) in dogs 
1141. 
The enteral feeding solution delayed stom- 
ach emptying for significantly longer periods of 
time. Dog no. 4 failed to show stomach empty- 
ing of the Heidelberg capsule in any of the stud- 
ies, and PHT plasma levels continued to rise 
over the sample period for each of the treat- 
ments. The data in dog no. 4, in particular, sug- 
gest that undissolved PHT is not emptying with 
the liquid. This occurrence would indicate either 
that PHT particles are adhering to stomach 
mucus or are aggregating in a size greater than 
1 mm in diameter [ 151. The hydrophobic na- 
ture of PHT solid material has resulted in ag- 
gregation of powder mass in dissolution studies 
performed at low pH (16) and is consistent with 
these in uiuo observations. 
Higher PHT plasma levels correlated with 
nutrient-induced delay of stomach emptying in 
dogs nos. 1 and 2; however, dogs nos. 3 and 4 
showed higher PHT plasma levels when nu- 
trient was co-administered even though the 
stomach-emptying pattern was similar be- 
tween treatments. In all four dogs, PHT plasma 
levels were highest with co-administered Os- 
molite, intermediate with glucose co-adminis- 
tration, and lowest in controls. 
The dog is not a good model for phenytoin 
bioavailability from oral dosage in humans be- 
cause of metabolic differences. The canine liver 
hydroxylates PHT at both the meta and para 
positions. The high capacity meta pathway is 
dominant in dogs [ 171. The para pathway is 
secondary in dogs while it is the dominant sat- 
urable pathway in other species, including hu- 
mans. As a result, elimination half-lives are 
much shorter in dogs than in humans [ 181. In- 
testinal residence time is also shorter in dogs 
than in humans. In this regard, the dog is a good 
model in which to study the impact of incom- 
plete drug dissolution on systemic availability. 
The use of a dog with a duodenal fistula al- 
lowed for separation of the nutrient effect from 
the stomach emptying event. Dilantin (PHT 
free acid) suspension (Parke Davis - Warner 
Lambert) was infused into the duodenum at a 
rate designed to mimic the glucose calorie con- 
trol afforded by the stomach-duodenal feed- 
back loop in a normal dog. This study showed 
the same PHT plasma profile versus treatment 
pattern that was observed in the dogs receiving 
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Fig. 1. PHT plasma concentrations and GI pH profiles vs. time from oral capsule dosage (15 mg/kg). Opposite page: (a) 
dog no. 1; (b) dog no. 2. This page: (c) dog no. 3; (d) dog no. 4. Key: 0, phenytoin alone, top GI pH profile; x , plus glucose, 
middle; * , plus Osmolite, bottom. 
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TABLE 1 
PHT plasma concentration vs. time parameters in dogs 
Dog Treatment C,,, AUCtoBh GET” 
@MI (ItMh) (h) 
1 control 1.0 2.7 0 
glucose 4.8 10.5 1.8 
Osmolite 4.1 16.8 >8 
2 control 1.1 3.9 1.1 
glucose 1.8 8.5 1.8 
Osmolite 3.7 17.0 5.4 
3 control 1.4 3.9 1.7 
glucose 2.4 12.4 1.9 
Osmolite 3.8 14.0 2.4 
4 control 4.0 11.8 >8 
glucose 5.2 28.6 >8 
Osmolite 7.4 42.2 >8 
Fistulated dog AUCto6h f/tMh) 
control 3.8 11.2 - 
glucose 5.8 29.0 - 
Osmolite 8.1 35.2 
“GET = gastric emptying time in hours. 
The results in dogs nos. 3 and 4, as well as in 
the dog with the duodenal fistula, indicate that 
the increased plasma levels of PHT in the fed 
state are not solely the result of increasing gas- 
tric residence time, thereby permitting a greater 
extent of drug dissolution. The in vitro studies 
suggest that fed-state bile salt concentrations 
increase the dissolution rate of PHT. Sodium 
taurocholate concentrations above the critical 
micelle concentration (3-4 r&f) increase 
phen~oin solubility and result in an increase 
in dissolution rate in the rotating disc experi- 
ments as shown in Fig. 2. 
Although the administered fluid volume was 
kept constant between treatments, different 
nutrient treatments may have stimulated fluid 
secretion in the stomach to different degrees. 
Greater fluid volume in the stomach would pro- 
vide greater dissolution capacity and result in 
an increase in dissolved PHT leaving the stom- 
ach with the emptying fluid. In addition, the 
choice of administered fluid volume ( 150 ml) is 
in a region where the fluid emptying pattern 
from the stomach is highly variable in dogs [ 19 1. 
Experiments designed to more clearly separate 
the volume and nutrient effects are currently 
underway. 
Drug and nutrient input into the dog duo- 
denal fistula bypassed both the stomach and bile 
duct. Yet a nutrient enhancement of PHT 
plasma levels was still observed. Since the nu- 
trient solutions were hyperosmolar, depression 
of intestinal motility, stimulation of intestinal 
secretions and increased availability of para- 
cellular pathways may have played a role in in- 
creasing PHT uptake. In the rat intestinal per- 
fusion studies, stomach emptying, bile input, 
and drug dissolution steps are bypassed by di- 
rect input of phenytoin iso-osmotic solutions 
into the intestine. Co-perfusion of glucose (20 
and 100 m&f) resulted in higher PHT permea- 
bilities and this increase was reversible by in- 
clusion of phlorizin, an inhibitor of active mu- 
cosal glucose transport [ 61 (Table 2). PHT 
permeabilities were less variable at 100 mM D- 
glucose than at 20 m&f and a greater degree of 
intestinal water absorption was observed at the 
higher glucose concentration (Table 2). PHT 
permeabilities were depressed at high calcium 
chloride concentrations (15-100 mikf) while 
they were unaffected by concentrations in the 
range of extracellular calcium concentrations 
(2-5 m&f). 
High incubation concentrations of calcium 
chloride also depressed initial rate uptake of 
PHI’ by intestinal rings while D-ghcOSe had no 
effect. Since this latter result was inconsistent 
with the in. situ perfusion data, a time course of 
PHI’ uptake by intestinal rings was conducted 
with, again, no effect of D-glucose on PHT up- 
take being detected (Fig. 3, Table 3). 
The phenytoin jejunal perfusion data are 
consistent with a recent conjecture [ 63 that in- 
testinal absorption of sodium-co-transported 
nutrients triggers the opening of paracellular 
pathways. This action would result in en- 
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Fig. 2. Cumulative mass appearing in dissolution media with time from rotating phenytoin disc dissolution as a function of 
medium sodium taurocholate (NaTc) concentration. Temp. = 37’ C, pH = 6.45, rotational speed = 200 rpm, tablet compres- 
sion = 2500 lbs/sq. in., and dissolution volume = 200 ml. Data points represent one set of experiments, n = 1. 
TABLE 2 
Dimensionless jejunal PHT membrane permeabilities a. PHT jejunal ring uptake @mol/g min) 
Treatment P,+ S.E.M. % water 
transport/cm’ 
Treatment Uptake + S.E.M. 
Control 8.0 + 1.59 
+ 5 n&f glucose 7.5+0.91 
+ 20 mM glucose 7.8+0.56 
+ 100 nuI4 glucose 8.6+0.65 
b. PHT duodenal ring uptake (flmol/g min) 
Control 
+ 20 mM glucose 




+ 20 mM glucose 
+ 0.5 rnM nhlorizin 
4.5+0.54 $0.1 
+ 50 mM calcium ’ *1.9+0.50 -0.2 
+ 2 mM calcium 4.7+ 1.55 -0.2 
*Significantly different (t-test p value < 0.05 for n = 8). 
B - : secretion; + : absorption. 
as an energy-conserving mechanism. Such a 
mechanism was postulated to account for effi- 
cient sugar absorption at lumenal concentra- 
tions in large excess of the K, (0.5-10 n-H) of 
the rat jejunal sodium-D-glucose co-trans- 
porter. Increased water absorption at high nu- 
trient concentrations suggests that local con- 
vection and solvent drag of solute may be 
operative, increasing solute absorption. Fur- 
thermore since all perfusion solutions were iso- 
osmolar, these forces could not be generated by 
TABLE 3 
Treatment Uptake + S.E.M. 
Control 9.0+0.43 
+ 10 mM calcium *6.0 + 0.43 
+ 40 mM calcium *6.4+0.51 
Three minute incubations at shaking rate 72 rpm. 
*Significantly different from controls (t-test p < 0.05 n = 8 
rings in 2 rats). 
lumenal osmolality differences. The data ap- 
pears more likely to be the result of intercellu- 
lar events related to transcellular nutrient 
transport. 
Opening of paracellular pathways in epithe- 
lia has been associated with removal of calcium 
from mucosal solutions [ 201. With this consid- 
eration, the agreement of the in situ and in vitro 
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Fig. 3. Rat jejunal ring phenytoin uptake with time in the presence and absence of 100 mM D-Glucose. Temp.=37’C, 
pH = 6.5, osmolarity = 300 mOsm/kg, shaking rate = 90 rpm. Values are the standard error of the mean, n = 12 for control 
and n = 9 for glucose. 
data suggest that high calcium levels may infiu- 
ence the paracellular pathway from the mu- 
cosal side. The disagreement between the two 
systems with respect to the influence of glucose 
on passive transport of solute suggests that an 
intact blood supply is a requirement. The role 
of basolateral membrane controls on intestinal 
glucose transport and the influence on passive 
intestinal drug transport is currently under 
investigation. 
The selectivity of this nutrient-controlled 
parallel absorption pathway should be a func- 
tion of both drug molecular size and polarity. 
Phenytoin is a small molecule that is un- 
charged at perfusion pH. The high lipophilicity 
of the drug suggests that pa~itioning into the 
mucosal membrane should not limit transcell- 
ular transport. Reduction of the aqueous resis- 
tance near the mucosal membrane by nutrient- 
induced water absorption coupled with result- 
ant solvent drag through nutrient-controlled 
paracellular pathways, however, may be play- 
ing a role to enhance PHT uptake. 
SUMMARY 
The potential in uiuo significance of a drug- 
nutrient interaction can often be projected 
based on the physicochemi~al properties of the 
drug which dictate limits to drug absorption 
rate. For phenytoin, these properties suggest 
that interactions affecting drug dissolution 
should dominate absorption variability. Exper- 
imental isolation of other components of drug 
transport, however, indicate that nutrient ef- 
fects at the level of the intestinal membrane 
barrier may be playing a more general role in 
drug absorption variability. The clinical impact 
of such variability for PHT may be damped in 
humans since metabolism is saturable within 
the dose range of phenytoin and may dominate 
absorption variability. However, the narrow 
therapeutic index of phenytoin suggests that 
absorption variability may have played a role 
in the case study nutrient interactions that have 
been reported in the clinics. 
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